Education
About Us
Working with TipRanks
Follow Us
Avita Medical (RCEL)
NASDAQ:RCEL
RCEL Stock Chart & Stats
$4.41
-$5.13(-36.49%)
At close: 4:00 PM EST
$4.41
-$5.13(-36.49%)
Day’s Range― - ―
52-Week Range$3.22 - $11.25
Previous CloseN/A
Volume824.49K
Average Volume (3M)178.66K
Market Cap
$134.47M
Enterprise Value$138.91M
Total Cash (Recent Filing)$23.31M
Total Debt (Recent Filing)$44.77M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Feb 12, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding30,493,110
10 Day Avg. Volume151,123
30 Day Avg. Volume178,659
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)73.64
Price to Sales (P/S)5.16
P/FCF Ratio-5.69
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue1.92
Enterprise Value/Gross Profit2.29
Enterprise Value/Ebitda-3.36
Forecast
1Y Price Target
$4.50Price Target Upside2.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical AdoptionIntegrated clinical and real-world evidence indicates the multi-platform wound care approach improves tissue-level healing and wound bed preparation, supporting broader clinical adoption and the potential for higher revenue per patient.
Commercial FocusConcentrated selling efforts targeting a defined set of high-value burn and trauma centers create a clear pathway to capture a significant acute wound care market and drive consistent product utilization.
Cost DisciplineSustained reductions in operating expenses have preserved cash and created a leaner cost structure that enhances the company's ability to sustain operations as utilization trends recover.
Bears Say
Leadership UncertaintyAn ongoing CEO transition creates uncertainty around strategic execution and could delay implementation of recovery initiatives and commercial acceleration.
Liquidity RiskA strained cash position and limited cash runway increase the likelihood of dilutive financing or operational constraints if revenue recovery stalls.
Revenue PerformancePrior revenue shortfalls and soft demand patterns leave the stock vulnerable if utilization does not rebound in line with management's growth expectations.
Avita Medical News
RCEL FAQ
What was Avita Medical’s price range in the past 12 months?
Avita Medical lowest stock price was $3.22 and its highest was $11.25 in the past 12 months.
What is Avita Medical’s market cap?
Avita Medical’s market cap is $134.47M.
When is Avita Medical’s upcoming earnings report date?
Avita Medical’s upcoming earnings report date is Feb 12, 2026 which is in 10 days.
How were Avita Medical’s earnings last quarter?
Avita Medical released its earnings results on Nov 06, 2025. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.332 by -$0.128.
Is Avita Medical overvalued?
According to Wall Street analysts Avita Medical’s price is currently Undervalued.
Does Avita Medical pay dividends?
Avita Medical does not currently pay dividends.
What is Avita Medical’s EPS estimate?
Avita Medical’s EPS estimate is -0.36.
How many shares outstanding does Avita Medical have?
Avita Medical has 30,493,110 shares outstanding.
What happened to Avita Medical’s price movement after its last earnings report?
Avita Medical reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.332. Following the earnings report the stock price went up 10.882%.
Which hedge fund is a major shareholder of Avita Medical?
Currently, no hedge funds are holding shares in RCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avita Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (2.04% Upside)
$4.50 (2.04% Upside)
Blogger Sentiment
Bullish
RCEL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 14.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.86%
12-Months-Change
Fundamentals
Return on Equity
-1746.27%
Trailing 12-Months
Asset Growth
-21.37%
Trailing 12-Months
Company Description
Avita Medical
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
RCEL Company Deck
RCEL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in reimbursement issues and cost management, alongside strategic expansions in Europe. However, these positive developments were offset by notable revenue declines, reduced revenue guidance, and financial adjustments indicating ongoing challenges. Despite improvements in operational efficiency and cash management, the financial outlook remains cautious.View all RCEL earnings summariesRCEL Revenue Breakdown
99.27% Commercial sales
0.67% Services for emergency preparedness
0.07% Deferred commercial revenue
RCEL Stock 12 Month Forecast
Average Price Target
$4.50
▲(2.04% Upside)
Technical Analysis
Ownership Overview
1.20% Insiders
6.57% Mutual Funds
0.26% Other Institutional Investors
86.44% Public Companies and
Individual Investors